Stimulant(s) studied | Study design | Patients studied | Clinical outcomes |
Traditional stimulants |
Adjunctive methylphenidate | Chart review, naturalistic | 16 adults (5 with comorbid ADHD, 11 with bipolar depression) | Improvements in depression, overall functioning, and ability to concentrate; sleep disturbance, irritability/agitation reported |
Adjunctive methylphenidate or racemic mixture of AMPH salts | Chart review of sedation and depressive symptoms | 8 adults (BD II) | Improved clinical impression of bipolar illness; no manic switches, changes in cycling patterns, or substance abuse noted |
Adjunctive methylphenidate | 12-week open study, bipolar depression | 12 adults (10 BD I, 2 BD II) | Significant clinical improvements in depressive symptoms; no change in manic symptoms; anxiety, agitation, and hypomania reported |
Multiple stimulants | Chart review, history of stimulants and bipolar illness course | 34 hospitalized adolescents | Prior stimulant treatment associated with earlier age of illness onset |
Adjunctive mixed amphetamine salts | Randomized, placebo-controlled; comorbid BD and ADHD | 30 children with ADHD symptoms stabilized on divalproex sodium | Decrease in ADHD symptoms with adjunctive amphetamine treatment but not with divalproex sodium alone; 1 case of mania |
Novel stimulant |
Adjunctive modafinil | Case series | Mixed sample of depressed adults (4 unipolar, 3 bipolar) | Significant improvement in depressive symptoms |
Adjunctive modafinil | Randomized, double-blind, placebo-controlled | 85 adults with bipolar depression | Treatment group showed greater response and remission of depressive symptoms compared with placebo group; no difference in development of manic symptoms |
ADHD: attention-deficit/hyperactivity disorder; AMPH: amphetamine; BD: bipolar disorder; NOS: not otherwise specified |
Комментариев нет:
Отправить комментарий